UMM Logo

Universitas Muhammadiyah Malang


Free Download Journals Directory


International Journal Of Bilogical Sciences

.: Home > International Journal Of Bilogical Sciences > 2015 > Volume 11 Number 2 > Qian Wang1, Tingqing Guo2, Jennifer Portas and Alexandra C. McPherron3

A Soluble Activin Receptor Type IIB Does Not Improve Blood Glucose in Streptozotocin-Treated Mice

Qian Wang1, Tingqing Guo2, Jennifer Portas and Alexandra C. McPherron3
Genetics of Development and Disease Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland, USA 1. Current Addresses: Pathology Department, Stony Brook University Medical Center, Stony Brook, New York, USA 2. Novo Nordisk Research Centre China, Changping District, Beijing, China 3. Myotherapeutics, Silver Spring, Maryland, USA  Corresponding author: Alexandra C. McPherron, Myotherapeutics, 10169 New Hampshire Ave. #149, Silver Spring, Maryland 20903, USA Email: amcpherron@myotherapeutics.com
Abstract :

Type 1 diabetes mellitus (T1DM), or insulin dependent DM, is accompanied by decreased muscle mass. The growth factor myostatin (MSTN) is a negative regulator of muscle growth, and a loss of MSTN signaling has been shown to increase muscle mass and prevent the development of obesity, insulin resistance and lipodystrophic diabetes in mice. The effects of MSTN inhibition in a T1DM model on muscle mass and blood glucose are unknown. We asked whether MSTN inhibition would increase muscle mass and decrease hyperglycemia in mice treated with streptozotocin (STZ) to destroy pancreatic beta cells. After diabetes developed, mice were treated with a soluble MSTN/activin receptor fused to Fc (ACVR2B:Fc). ACVR2B:Fc increased body weight and muscle mass compared to vehicle treated mice. Unexpectedly, ACVR2B:Fc reproducibly exacerbated hyperglycemia within approximately one week of administration. ACVR2B:Fc treatment also elevated serum levels of the glucocorticoid corticosterone. These results suggest that although MSTN/activin inhibitors increased muscle mass, they may be counterproductive in improving health in patients with T1DM.

Keywords :
activin receptor, glucocorticoid, myostatin, muscle hypertrophy, type 1 diabetes

Date Deposited : 17 Feb 2016 11:32

Last Modified : 17 Feb 2016 11:32

Official URL: http://www.ijbs.com/v11i2

Volume 11, Number 2, - 2015 , ISSN 1449-2288

Download:
Full Text Original
Abstract : pdf doc